PER Stock Overview
Engages in the research and development of novel antisense pharmaceuticals in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Percheron Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.075 |
| 52 Week High | AU$0.10 |
| 52 Week Low | AU$0.049 |
| Beta | 0.85 |
| 1 Month Change | -6.25% |
| 3 Month Change | 7.14% |
| 1 Year Change | 8.70% |
| 3 Year Change | -58.33% |
| 5 Year Change | 36.36% |
| Change since IPO | -42.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| PER | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -6.3% | -0.1% | -0.9% |
| 1Y | 8.7% | 46.4% | 7.4% |
Return vs Industry: PER underperformed the Australian Pharmaceuticals industry which returned 46.4% over the past year.
Return vs Market: PER exceeded the Australian Market which returned 7.4% over the past year.
Price Volatility
| PER volatility | |
|---|---|
| PER Average Weekly Movement | 14.7% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: PER's share price has been volatile over the past 3 months.
Volatility Over Time: PER's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | James Garner | www.PercheronTx.com |
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company’s product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial.
Percheron Therapeutics Limited Fundamentals Summary
| PER fundamental statistics | |
|---|---|
| Market cap | AU$70.32m |
| Earnings (TTM) | -AU$10.85m |
| Revenue (TTM) | AU$2.29m |
28.8x
P/S Ratio-6.1x
P/E RatioIs PER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PER income statement (TTM) | |
|---|---|
| Revenue | AU$2.29m |
| Cost of Revenue | AU$56.95k |
| Gross Profit | AU$2.23m |
| Other Expenses | AU$13.08m |
| Earnings | -AU$10.85m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 97.51% |
| Net Profit Margin | -474.51% |
| Debt/Equity Ratio | 0% |
How did PER perform over the long term?
See historical performance and comparison